News Focus
News Focus
Followers 35
Posts 1202
Boards Moderated 1
Alias Born 08/27/2000

Re: Protector post# 279791

Tuesday, 11/29/2016 12:02:11 PM

Tuesday, November 29, 2016 12:02:11 PM

Post# of 347009

goodJohn, that is incorrect. Bavituximab performed as expected. See official communications on the topic.



Then those responsible for trial design failed. And what is "performed as expected"?

As expected in relation to unreliable phase II data?? You're thought process proves that Phase II should have been redone.

If the control arm doesn't exceed then the trial wouldn't have been stopped and the stat. sig. improvement that PPHM communicated later would have been obtained in a blinded way good to file for approval.



One big pie wheel in the sky. See above..

Maybe reliable Phase II data shows 2tonelephant, and Sunrise is designed with such knowledge.

BTW, can anyone tell me what the optimal dosage of bavituximab is? Oh wait, we don't have reliable data for this knowledge.. But go ahead and spend millions on Sunrise? Total failure in thinking, IMO.

All the best,
John

Disclaimer: Every post, and all my views are only speculative. Do not invest money or any other resources based on these post or opinions. Best of luck and do your own due diligence!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y